Financial Risks Preventing Research for AIDS Vaccine

Scientific and financial risks are preventing a number of biotechnology and pharmaceutical companies from making huge investments with their own funds in AIDS vaccine research. Companies fear that they might not be able to recover their long term investment in drug research as HIV is quite prevalent in developing countries which are unable to afford such costly treatments. Though there has been an increase in worldwide funding for AIDS and also philanthropic and federal funding has seen a rise but investment from the private sector has decreased. There is an increased requirement for the participation of industry in the fight against AIDS as it involves a disciplined approach in project management and clinical trials.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>